Akebia Therapeutics, Inc. - Common Stock (AKBA)
2.2600
+0.5700 (33.73%)
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease
The company is primarily engaged in addressing unmet medical needs in anemia caused by chronic kidney disease, aiming to enhance patient outcomes through its proprietary treatments and drug candidates. Akebia's research and development efforts are centered around creating therapies that improve the management of renal diseases by promoting better health and quality of life for patients suffering from kidney-related conditions.

Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · March 14, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · March 14, 2025

Via Benzinga · March 14, 2025

AKBA stock results show that Akebia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

Via Benzinga · April 10, 2024

Via Benzinga · March 28, 2024

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval in 37 countries.
Via Benzinga · March 28, 2024

Shares of RH (NYSERH) rose sharply in today’s pre-market trading following the release of quarterly results.
Via Benzinga · March 28, 2024

Via Benzinga · March 28, 2024

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.
Via Benzinga · March 27, 2024

Shares of Westport Fuel Systems Inc. (NASDAQWPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
Via Benzinga · March 26, 2024

Via Benzinga · March 15, 2024

It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!
Via InvestorPlace · March 15, 2024

AKBA stock results show that Akebia Therapeutics beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 14, 2024

Via Benzinga · March 14, 2024

HC Wainwright has upgraded Akebia Therapeutics Inc (NASDAQAKBA) from Neutral to Buy rat
Via Benzinga · August 28, 2023

Companies Reporting Before The Bell • Pharming (NASDAQPHAR) is projected to report earnings for its fourth quarter.
Via Benzinga · March 14, 2024

Via Benzinga · August 28, 2023